Savara Inc. (SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, has a clinical trial milestone to watch in the near future.
The top-line data from the company's IMPALA-2 trial is expected to be announced by the end of this quarter (Q2, 2024).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com